about
Bisphosphonates: mechanism of action and role in clinical practiceOnce-yearly zoledronic acid in hip fracture preventionCompliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISAThe association between compliance and persistence with bisphosphonate therapy and fracture risk: a reviewImplementing adherence to osteoporosis treatments.Adoption of once-monthly oral bisphosphonates and the impact on adherence.An observational study of musculoskeletal pain among patients receiving bisphosphonate therapyLong-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribingBone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.Adherence to osteoporosis treatments: room for improvementClinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI studyOnce-monthly risedronate for postmenopausal osteoporosisOral bisphosphonate compliance and persistence: a matter of choice?Adherence and occurrence of fractures after switching to once-monthly oral bisphophonatesTreatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST studyEfficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trialsA reappraisal of generic bisphosphonates in osteoporosis.Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture.Denosumab in postmenopausal osteoporosis: what the clinician needs to know.Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.Discovery, clinical development, and therapeutic uses of bisphosphonates.A qualitative study of community pharmacists' opinions on the provision of osteoporosis disease state management services in Malaysia.Where now for the management of osteoporosis?Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.Bisphosphonates for the treatment of osteoporosis: insights for clinicians.How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women.RANK ligand inhibition with denosumab for the management of osteoporosis.The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapyRisedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs.Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinionsDenosumab: an investigational drug for the management of postmenopausal osteoporosisManagement of osteoporosis in the aging male: focus on zoledronic acid.Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.Denosumab for the treatment of postmenopausal osteoporosis.Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database.
P2860
Q24644708-D6C4FEEC-9580-4D95-8775-E782247DFE53Q24657667-776731EA-7005-448A-AEAE-ABC8C1A6EF95Q30988951-EDCDECBD-B293-4501-A8DE-42B220380243Q33300458-BDB1E982-DCE7-4F75-9960-C4C568D4CF2BQ33610273-787A73BE-B77A-49BE-85E2-FEF467A7565FQ33701964-00F7BE51-B1E5-4D01-96AA-609CE08D86EFQ33765055-23DE76F4-F90A-4E74-91B6-478B2AB8FF7CQ33874953-87960ECC-B687-4565-96E4-E5A63B51D15EQ33966587-A1A26F93-E30F-42DB-82CA-5270E190CEF1Q34033742-5F543424-2EA3-435E-B4FF-4736BCE91D60Q34051900-D56017FA-BB1C-46E8-88BE-30B6A88DCFFEQ34272000-ACBE78CD-8548-4A07-A853-EC8E9551B394Q34472700-17587804-35B5-4FC3-B37B-FB0A396DE22EQ34821660-96715A7D-E9E8-47F7-82AB-86326A5581B6Q35105035-618C43B6-9A80-4E6C-84E8-EDB98FF37D9BQ35331699-383BC2CE-7517-439F-B0A8-5C3EE38EB189Q35644168-F8E78E85-EDA8-4A03-B807-6142450C7B98Q36056911-8317BAAF-022E-4D4E-85D1-E28F43E9A8A6Q36056922-837D7B25-29F0-4FA1-A68E-58789C6CCE05Q36059331-3C2CFC03-AB12-4C69-B580-1326724D4E21Q36065420-471B662F-BB0F-4B2D-B2A1-ADEC90AB48D7Q36117668-D74926F6-59C3-4C3D-8FB9-AF89836875D4Q36141816-A8A931A4-B41D-4E0E-8888-A987D6BE4285Q36283739-6ED2088D-E7ED-4CCA-AD71-CACF1EB41763Q36443681-F985333D-500C-41B5-AB4A-D18505AA1F47Q36492900-CBE05FA4-9571-45AE-9F61-CACE0604F04DQ36516518-C521030D-33B6-484B-B65F-C5C9D01EE7A1Q36600255-F1866999-A044-46F8-B19E-9E582A904536Q36829073-5FF5A6C9-F230-4A6F-99B6-AFC73CFCB751Q36897425-778DE650-F44B-456C-B870-C2EE073B41ECQ36897441-45DB6ABE-EC30-4D20-9A77-D585396E94C5Q36952170-0B54C8AD-0ABD-411C-8F92-80A9DC676E73Q36979427-3FA171F7-BE64-4BA0-BD44-C9CC6D05E137Q37058784-03D91B74-73A5-4125-B88F-6083232D5E3FQ37307805-557CF4A9-9687-4144-BB7D-F8242C3B2C1CQ37337113-CD69C74D-9326-47AE-8279-5FE6E43C7675Q37337267-D9E4F952-F876-48FD-ACF7-1DA1A4A4C036Q37360702-5B5FA9B4-699C-47D2-8396-46D9B48B4541Q37411037-7D237F52-CD85-489E-96AB-26BDCC98528EQ37429327-04C336A2-0106-4B16-8A84-80F3791E2416
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Compliance with pharmacologic therapy for osteoporosis.
@en
Compliance with pharmacologic therapy for osteoporosis.
@nl
type
label
Compliance with pharmacologic therapy for osteoporosis.
@en
Compliance with pharmacologic therapy for osteoporosis.
@nl
prefLabel
Compliance with pharmacologic therapy for osteoporosis.
@en
Compliance with pharmacologic therapy for osteoporosis.
@nl
P2093
P1476
Compliance with pharmacologic therapy for osteoporosis.
@en
P2093
Barbara Edelman Lewis
Eva Lydick
John I Reed
Mary Charpentier
Robert A Yood
Srinivas Emani
P2888
P304
P356
10.1007/S00198-003-1502-4
P407
P577
2003-09-19T00:00:00Z